Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.

ABSTRACT: Glioblastomas remain the deadliest brain tumour, with a dismal ∼12-16-month survival from diagnosis. Therefore, identification of new diagnostic, prognostic and therapeutic tools to tackle glioblastomas is urgently needed. Emerging evidence indicates that the cellular machinery controlling the splicing process (spliceosome) is altered in tumours, leading to oncogenic splicing events associated with tumour progression and aggressiveness. Here, we identify for the first time a profound dysregulation in the expression of relevant spliceosome components and splicing factors (at mRNA and protein levels) in well characterized cohorts of human high-grade astrocytomas, mostly glioblastomas, compared to healthy brain control samples, being SRSF3, RBM22, PTBP1 and RBM3 able to perfectly discriminate

SUBMITTER: Fuentes-Fayos AC 

PROVIDER: S-EPMC7904102 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature